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ABSTRACT
Introduction: Type 2 diabetes mellitus (T2DM)
progression often results in treatment
intensification with injectable therapy to
maintain glycemic control. Using pilot data
from the Initiation of New Injectable Treatment
Introduced after Anti-diabetic Therapy with
Oral-only Regimens study, real-world
treatment patterns among T2DM patients
initiating injectable therapy with insulin
glargine or liraglutide were assessed.
Methods: This was a retrospective analysis of
claims from the OptumInsightTM (OI; January 1,
2010 to July 30, 2010) and HealthCore (HC;
January 1, 2010 to June 1, 2010) health
insurance databases. Baseline characteristics,
health care resource utilization, and costs were
compared between adults with T2DM initiating
injectable therapy with insulin glargine
pen versus liraglutide. Follow-up outcomes,
including glycated hemoglobin A1c (A1C),
hypoglycemia, health care utilization, and
costs, were assessed.
Results: At baseline, almost one in three
liraglutide patients (OI, n = 363; HC, n = 521)
had A1C\7.0%, while insulin glargine patients
(OI, n = 498; HC, n = 1,188) had poorer health
status, higher A1C (insulin glargine: 9.8% and
9.1% versus liraglutide: 7.9% and 7.7%, OI and
HC, respectively, both P\0.001), and were less
likely to be obese (insulin glargine: 10.8% and
9.2% versus liraglutide: 17.4% and 18.8%, OI
and HC, respectively, both P\0.01). The
percentage of patients experiencing a
hypoglycemic event was numerically higher
for insulin pen use for both cohorts (OI 4.4%
versus 3.0%; HC 6.2% versus 2.3%). During
follow-up, in the insulin glargine cohort,
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annualized diabetes-related costs remained
unchanged ($8,344 versus $7,749 OI, and
$7,094 versus $7,731 HC), despite a significant
increase in pharmacy costs, due to non-
significant decreases in medical costs, while
the liraglutide cohort had a significant increase
in annualized diabetes-related costs ($4,510
versus $7,731 OI, and $4,136 versus $7,111
HC; both P\0.001) due to a non-significant
increase in medical costs coupled with a
significant increase in pharmacy costs.
Conclusion: These descriptive data identified
differences in demographic and baseline clinical
characteristics among patients initiating
injectable therapies. The different health care
utilization and cost patterns warrant further
cost-effectiveness analysis.
Keywords: Type 2 diabetes mellitus; Health
care costs; Injectable treatment; Treatment
initiation
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a progressive
disease. Although treatment with an oral anti-
diabetic drug (OAD), usually metformin, in
combination with lifestyle changes is
recommended as the initial therapy for most
patients, worsening b-cell function typically
requires intensification of therapy with basal
or intermediate-acting insulin (e.g., insulin
glargine, insulin detemir, or neutral protamine
Hagedorn) or glucagon-like peptide-1 (GLP-1)
receptor agonists (such as liraglutide) [1].
Initiating injectable therapy may be delayed
by negative perceptions from patients and
health care professionals, including fear of
injection pain, misconceptions about insulin
risks (e.g., hypoglycemia and weight gain),
attributing the need for insulin to personal
failure, and the perceived negative impact on
the patient’s social life and job [2–4].
Insulin has traditionally been administered
using a vial and syringe. Delivering insulin via
pen devices may help address some of the
barriers to insulin initiation, including
improved convenience and discretion and ease
of use [5, 6] that may ultimately also improve
outcomes [7–9]. The GLP-1 receptor agonist,
liraglutide, is dispensed only in a prefilled pen
device, and the insulin analog, insulin glargine,
is also available in a prefilled pen device.
The Initiation of New Injectable Treatment
Introduced after Anti-diabetic Therapy with
Oral-only Regimens (INITIATOR) study
expands on earlier clinical trial data [10] by
investigating real-world outcomes among
patients with T2DM failing OADs and
initiating injectable therapy with insulin
glargine or liraglutide, both delivered by
prefilled pen device. This analysis reports
treatment pattern data from the pilot
retrospective study phase of INITIATOR.
METHODS
Study Design and Patients
This retrospective analysis used medical and
pharmacy claims, enrollment information, and
linked electronic laboratory results from two
independent administrative claims databases
associated with OptumInsightTM (OI; Eden
Prairie, MN, USA) and HealthCore (HC;
Wilmington, DE, USA) in the United States
(US). Commercially insured adults (and
Medicare Advantage adults in the HC
database) were eligible for the study if they
were aged 18 years or older and had T2DM,
defined as having one or more inpatient visits
or two or more outpatient visits (C30 days
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apart) with a primary or secondary diagnosis of
T2DM [International Classification of Diseases,
9th Revision, Clinical Modification (ICD-9-CM)
codes: 250.x0 or 250.x2], as used in previously
published claims-database studies [11–13]. To
be included, patients were required to have
initiated either insulin glargine by prefilled pen
device or liraglutide (with index date as the
earliest fill) between January 1, 2010 and June
30, 2010 (HC) or July 31, 2010 (OI) and have
received one or more OAD in the 6 months
before the index date (baseline). Patients were
required to have continuous medical and
pharmacy benefits for the baseline period and
9 (OI) or 12 (HC) months after index date
(follow-up). In the OI database only, one or
more glycated hemoglobin A1c (A1C) values
in the baseline period through 15 days
following the index date was also an
inclusion criterion. In the A1C analyses, for
consistency, a sub-sample of patients with
available baseline A1C values was used in the
HC database as well.
Patients were excluded from the study if they
met any of the following criteria: one or more
pharmacy claims for insulin, exenatide,
liraglutide, or pramlintide during the baseline
period; pharmacy claims for both insulin
glargine (in either pen or vial form) and
liraglutide on the index date; pharmacy claims
for insulin glargine in prefilled pen format and
insulin glargine in other forms (vial-and-
syringe, reusable pen) on the index date.
Patients with Medicare Supplemental or Part D
were excluded, as not all claims are available for
these patients; the HC database retained
patients with Medicare Advantage enrollment,
as they have full claims representation.
This retrospective analysis is based on
previously collected data and does not involve
any new studies of human subjects performed
by any of the authors.
Baseline Measures
Baseline factors were recorded, including
demographics, comorbidities [including
modified Quan–Charlson comorbidity index
(QCI) [14] and obesity as identified with
ICD-9-CM codes], hypoglycemic events,
prescription drug usage, and, where available,
A1C. Health care resource utilization included
emergency department (ED) visits, inpatient
hospitalizations, ambulatory visits, and
endocrinologist visits, as well as any
hospitalization in the 30 days before the index
date. Diabetes-related health care resource
utilization was also analyzed and included
claims with a primary or secondary diagnosis
of diabetes (ICD-9-CM: 250.xx). Health
care costs were computed as the combined
patient- and plan-paid amounts of adjudicated
claims. Costs were adjusted to 2011 US
dollars using the medical care component of
the US consumer price index [15]. Diabetes-
related health care costs included costs from
medical claims with a primary or secondary
diagnosis of diabetes (ICD-9-CM: 250.xx), anti-
diabetic medications, glucose meters, and test
strips.
Endpoint Measures
Clinical outcomes analyzed at follow-up
(9 months for OI and 12 months for HC)
were A1C change from baseline, treatment
persistence, daily average consumption
(DACON), and hypoglycemia. Treatment
persistence was defined as remaining on the
study drug during the follow-up period without
discontinuation or switching after study drug
initiation [16–19] and medication was
considered discontinued if the prescription
was not refilled within the expected time of
medication coverage (the 90th percentile of
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the time, stratified by the metric quantity
supplied, between first and second fills among
patients with at least one refill in the specific
cohort, irrespective of post index eligibility).
Patients who restarted their initial medication
after having met the criteria for discontinuing
their index medication were considered to be
non-persistent. For patients using the insulin
glargine pen, persistence rates were based on all
insulin glargine fills because patients on insulin
glargine pen could switch to vial-and-syringe as
their insulin delivery device but would still be
on insulin glargine treatment. DACON was
calculated as the total amount of medication
(units or mg) dispensed before the last refill of
the study drug divided by the total number of
days between initiation and last refill during
follow-up. While DACON is not comparable
between insulin glargine and liraglutide
medications, it was reported as part of the
respective cohort profiles. Hypoglycemia was
defined as a health care encounter (outpatient,
inpatient, or ED visit) with a primary or
secondary ICD-9-CM diagnosis code for
hypoglycemia (ICD-9 code 250.8x–diabetes
with other specified manifestations; 251.0–
hypoglycemic coma; 251.1–other specified
hypoglycemia; or 251.2–hypoglycemia,
unspecified) [20].
Due to the differences in the baseline
demographics and clinical characteristics of
these treatment groups, clinical outcomes
were described, and health care resource
utilization and costs were compared between
baseline and follow-up within each treatment
group, rather than comparing outcomes
between treatment groups. Follow-up health
care costs (adjusted to 2011 US dollars) and
resource utilization were also computed, using
definitions consistent with those created in the
baseline period.
Statistical Analysis
This study used an intent-to-treat approach, in
which patients who augmented or switched
from their initial treatment regimen were
retained in their assigned cohort. This
approach best captures what the prescribing
physician intended for the patient to take.
Furthermore, any deviations from the initial
treatment are reflective of how the medication
is being used in the real-world setting. Baseline
characteristics, treatment patterns, and
outcomes among the insulin glargine pen and
liraglutide groups were assessed descriptively.
Baseline characteristics and study outcomes
were compared using unadjusted statistical
comparisons for both study cohorts.
Continuous variables were compared using
Student t tests (for the OI cohort) or Student
t tests and Wilcoxon rank-sum tests (for the HC
cohort), while categorical variables were
compared using Fisher exact tests (for the OI
cohort) and v2 tests (for the HC cohort),
depending on the distribution of the measure.
Due to demographic and clinical differences
observed in the insulin glargine pen and
liraglutide cohorts during the baseline period,
follow-up outcomes were assessed descriptively.
Within each treatment group, annualized
diabetes-related health care costs were
compared between the baseline and follow-up
periods using paired t tests. The statistical
analyses were performed with SAS version 9.2
(SAS Institute Inc., Cary, NC, USA; 2008).
RESULTS
Baseline Patient Characteristics
Data from a total of 2,570 patients were
included: 861 OI (insulin glargine pen n = 498,
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Table 1 Baseline characteristics (intent-to-treat population)












Age, years, mean (SD) 53.1 (9.38) 52.8 (8.33) 0.598 56.9 (11.90) 53.2 (9.02) \0.001
Age category, years, n (%)
18–39 44 (8.8) 25 (6.9) 80 (6.7) 39 (7.5)
40–64 414 (83.1) 321 (88.4) 0.097 860 (72.4) 448 (86.0) \0.001
65–74 37 (7.4) 17 (4.7) 148 (12.5) 32 (6.1)
C75 3 (0.6) 0.0 100 (8.4) 2 (0.38)
Male, n (%) 295 (59.2) 185 (51.0) 0.018 685 (57.7) 249 (47.8) \0.001
QCI, mean (SD) 0.99 (1.64) 0.61 (1.13) \0.001 1.05 (1.67) 0.73 (1.28) \0.001
Comorbidities, n (%)
Hypoglycemia* 16 (3.2) 6 (1.7) 0.191 39 (3.3) 12 (2.3) 0.273
Obesity 54 (10.8) 63 (17.4) 0.007 109 (9.2) 98 (18.8) \0.001
Hypertension 334 (67.1) 260 (71.6) 0.157 749 (63.1) 345 (66.2) 0.209
Hyperlipidemia 372 (74.4) 304 (83.8) 0.001 693 (50.3) 355 (68.1) \0.001
Neuropathy 53 (10.6) 17 (4.7) 0.001 112 (9.4) 37 (7.1) 0.117
Nephropathy 26 (5.2) 8 (2.2) 0.032 57 (4.8) 23 (4.4) 0.730
Retinopathy 41 (8.2) 18 (5.0) 0.075 123 (10.4) 30 (5.8) 0.002
Hypoglycemia, events per 100
patient years
11 4 16 6
Glycated hemoglobin A1c,
mean, % (SD)a
9.78 (2.19) 7.93 (1.56) \0.001 9.09 (1.90) 7.68 (1.38) \0.001
OADs, n (%)
Metformin 407 (81.7) 304 (83.75) 0.467 889 (74.8) 441 (84.6) \0.001
DPP-4 inhibitor 158 (31.7) 129 (35.5) 0.243 354 (29.8) 136 (26.1) 0.120
Meglitinide derivative 22 (4.4) 8 (2.2) 0.092 60 (5.1) 13 (2.5) 0.016
Sulfonylurea 322 (64.7) 157 (43.3) \0.001 749 (63.1) 223 (42.8) \0.001
Thiazolidinedione 174 (34.9) 148 (40.8) 0.087 390 (32.8) 187 (35.9) 0.218
a-Glucosidase inhibitor 4 (0.8) 3 (0.8) 1.000 15 (1.3) 4 (0.8) 0.369
Number of OADs, mean (SD) 2.18 (0.87) 2.06 (0.92) 0.053 2.07 (0.89) 1.93 (0.85) 0.003
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liraglutide n = 363) and 1,709 HC (insulin
glargine pen n = 1,188, liraglutide n = 521).
There were substantial differences in the
demographics and baseline clinical
characteristics between patients initiating
insulin glargine pen and those initiating
liraglutide (Table 1). In both databases,
patients initiating insulin glargine pen were
more likely to be male, have poorer baseline
health (as measured by the modified QCI), and
be treated with sulfonylureas at baseline.
Patients initiating treatment with liraglutide
were more likely to be obese or have
hyperlipidemia.
Baseline A1C measures were available for all
patients included from the OI database, and in
this database the insulin glargine pen cohort
had a higher mean A1C than the liraglutide
group (insulin glargine: 9.8% and 9.1% versus
liraglutide: 7.9% and 7.7%, OI and HC,
respectively, both P\0.001; Table 1). Prior to
injectable therapy initiation, A1C was already
within the American Diabetes Association target
range of \7.0% [1] for more of the liraglutide-
using patients than the insulin glargine pen
Table 1 continued












Diabetes-related health care utilization, n (%)
Emergency department visit 28 (5.6) 3 (0.8) \0.001 71 (6.0) 25 (4.8) \0.001
Endocrinologist visit 122 (24.5) 103 (28.4) 0.209 252 (21.2) 168 (32.3) 0.324
Ambulatory visit 470 (94.4) 347 (95.6) 0.531 1,106 (93.1) 499 (95.8) 0.033
Hospitalization\30 days before
initiation
27 (5.4) 1 (0.3) \0.001 45 (3.8) 4 (0.77) \0.001
OI: insulin glargine n = 498, liraglutide n = 363; HC: insulin glargine n = 283, liraglutide n = 113
OAD oral anti-diabetic drug, SD standard deviation, QCI modiﬁed Quan–Charlson Comorbidity Index
* Patients with C1 hypoglycemic event. aAmong patients with A1C test results available
Fig. 1 Glycated hemoglobin A1c category at baseline for
patients initiating insulin glargine or liraglutide in the
OptumInsight (a) and HealthCore (b) databases
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initiators (29.5% versus 9.2%, P\0.001), while
baseline A1C was C9.0% for fewer of the
liraglutide initiators compared to insulin
glargine pen initiators (21.8% versus 60.0%,
P\0.001; Fig. 1). Among patients in the HC
database with baseline A1C data available
[insulin glargine pen n = 283 (24%), liraglutide
n = 113 (22%)], baseline mean A1C levels were
also higher among those using the insulin
glargine pen compared to liraglutide. In this
subset, baseline A1C was also \7.0% for more
patients using liraglutide than insulin glargine
pen (33.6% versus 11.3%, P\0.001) and C9.0%
for more patients with insulin glargine pen than
liraglutide (47.7% versus 16.8%, P\0.001).
Hypoglycemia during the baseline period was
infrequent in both groups (Table 1).
Baseline health care utilization and costs
were significantly different between cohorts,
with a higher percentage of insulin glargine
patients experiencing diabetes-related ED visits
and hospitalizations in the 30 days prior to
injectable therapy initiation (Table 1).
Annualized all-cause total health care costs at
baseline were either similar or higher for the
insulin glargine pen cohort versus the liraglutide
cohort, depending on the database [OI $15,050
(median $5,708) versus $10,812 ($6,541),
P = 0.020; HC $15,899 ($6,637) versus $11,912
($7,608), P = 0.137]. The annualized diabetes-
related costs for insulin glargine pen initiators
compared to liraglutide initiators followed a
similar pattern [OI $8,344 ($2,269) versus
$4,510 ($2,503), P = 0.006; HC $7,094 ($2,478)
versus $4,136 ($2,164), P = 0.126; Fig. 2].
Follow-up Clinical and Economic
Outcomes
For those patients with A1C values available at
both baseline and follow-up, mean A1C
reduction with insulin glargine pen was 1.11%
over 9 months (OI; n = 253 with mean baseline
A1C = 9.65%) and 0.75% over 12 months (HC;
n = 86 with mean baseline A1C = 8.97%). Mean
A1C reduction with liraglutide was 0.58% over
9 months (OI; n = 174 with mean baseline
A1C = 8.00%) and 0.38% over 12 months (HC;
n = 40 with mean baseline A1C = 7.61%). In
patients with A1C C7.0% at baseline (OI:
insulin glargine n = 229 with mean baseline
A1C = 9.98%, liraglutide n = 125 with mean
baseline A1C = 8.66%; HC: insulin glargine
n = 79 with mean baseline A1C = 9.20%,
liraglutide n = 26 with mean baseline
A1C = 8.31%), A1C \7.0% was reached during
follow-up in 21% and 15% with insulin glargine
and 34% (OI) and 38% (HC) with liraglutide.
Treatment persistence among patients using
insulin glargine was 61% in the OI database and
60% in the HC database. For patients using
liraglutide, treatment persistence was 52% in
the OI database and 51% in the HC database.
Mean persistence duration was 233 days and
305 days for insulin glargine and 207 days and
264 days for liraglutide in the OI (follow-up
270 days) and HC databases (follow-up
365 days), respectively (Fig. 3). The DACON of
insulin glargine was 29.9 and 28.0 IU, and the
DACON for liraglutide was 1.14 and 1.44 mg,
for the OI and HC databases, respectively.
The hypoglycemia event rate for insulin
glargine pen users was 0.11 (OI database) and
0.25 (HC database) events per patient year; for
liraglutide users, it was 0.06 events per patient
year in both databases. The percentage of
patients experiencing a hypoglycemic event in
the 9-month follow-up of the OI database was
4.4% and 3.0% for the insulin glargine pen and
liraglutide cohorts, respectively. For the HC
database the percentage experiencing at least
one hypoglycemic event in the 12-month
follow-up was 6.2% with insulin glargine pen
and 2.3% with liraglutide.
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During 9-month (OI database) and 12-month
(HC database) follow-up, respectively, a
diabetes-related ED visit occurred in 5% and
12% of patients with insulin glargine and 2%
and 7% of patients with liraglutide.
Furthermore, a diabetes-related ambulatory
visit occurred in 97% and 98% of patients with
insulin glargine and 94% and 98% of patients
with liraglutide. Finally, an endocrinologist visit
occurred for 33% and 30% of patients with
insulin glargine and 31% and 34% of patients
with liraglutide. Total annualized all-cause
health care costs in the follow-up period for
the insulin glargine pen cohort were $16,078
(median $7,449) and $16,466 ($9,183) for the OI
and HC databases, respectively. Annualized
diabetes-related costs among insulin glargine
pen-using patients remained similar from
baseline to follow-up in both the OI and HC
databases ($8,344 versus $7,749 OI, and $7,094
versus $7,731 HC; Fig. 2). There was a significant
increase in pharmacy costs in the follow-up
Fig. 2 Annualized mean diabetes-related health care costs
at baseline and during follow-up among insulin glargine and
liraglutide patients from the OptumInsight (a) and Health-
Core (b) Databases. All other differences were not
statistically different. Diabetes-related health care costs
included costs from medical claims with a primary or
secondary diagnosis of diabetes (ICD-9-CM: 250.xx),
or pharmacy claims for diabetes medication including
oral anti-diabetes drugs, insulin, glucagon-like peptide-1
receptor agonists, and pramlintide. N/A not applicable
Adv Ther (2013) 30:1128–1140 1135
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period in both databases, but this was offset by
non-significant decreases in diabetes-related
medical costs (Fig. 2). For the liraglutide
initiators, total annualized health care costs in
the follow-up period were $15,410 ($9,919) and
$14,579 ($10,244) in the OI and HC databases,
respectively. Annualized diabetes-related costs
among patients initiating liraglutide increased
from baseline to follow-up in both the OI and
HC databases ($4,510 versus $7,731 OI, and
$4,136 versus $7,111 HC; both P\0.001; Fig. 2).
There was a significant increase in pharmacy
costs for both databases, with smaller increases
for medical costs (which did not meet statistical
significance), contributing to the higher
diabetes-related costs.
DISCUSSION
This retrospective study of real-world treatment
of patients with T2DM failing OADs and
initiating injectable therapy with insulin
glargine pen or liraglutide showed that insulin
glargine and liraglutide pen devices are
prescribed to very different types of patients.
Patients using insulin glargine had a higher
mean QCI, a lower prevalence of obesity, and
higher mean A1C than those using liraglutide.
In addition, more insulin glargine initiators had
A1C C9.0%, while a greater proportion of
patients initiating liraglutide had an A1C
\7.0% at baseline. These baseline differences
suggest that a significant number of patients
initiating liraglutide may be more likely to have
achieved glycemic control prior to the initiation
of injectable therapy, and therefore the
medication may not have been prescribed
primarily for this purpose. When A1C is
C9.0%, insulin is considered to be more
effective than most other agents as a third line
therapy [1], which may also account for the
high mean A1C levels found in those initiating
insulin glargine pen in this study. The higher
prevalence of obesity among patients initiating
liraglutide in this study may also reflect the
perception, due to recent reports of clinical trial
results [21, 22], that this agent may be beneficial
for weight loss; however, data on weight or
body mass index (BMI) were not captured in
this pilot analysis to confirm this. Such
differences in baseline patient characteristics
offer challenges to conducting comparative
effectiveness research and in interpreting the
results of these studies and, therefore, must be
taken into account when such comparative
effectiveness studies are designed.
Changes in costs between baseline and
follow-up after initiating injectable therapy
differed between treatment groups. After
Fig. 3 Kaplan–Meier curve for the time to treatment
discontinuation for insulin glargine and liraglutide in the
OptumInsight (a) and HealthCore (b) databases
1136 Adv Ther (2013) 30:1128–1140
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initiating insulin glargine pen, the diabetes-
related health care costs in the follow-up period
remained similar to baseline despite an increase
in pharmacy costs. This is explained by the
offset resulting from a non-significant decrease
in diabetes-related medical costs, driven by
lower inpatient costs. For patients initiating
liraglutide, the diabetes-related health care costs
increased by almost 75% in the follow-up
period compared to baseline; this was due to
increases in both diabetes-related pharmacy and
inpatient costs. Direct comparisons in costs
between patients initiating treatment with
insulin glargine versus liraglutide would not
be appropriate without further adjustments,
given the likely confounding influence of
baseline patient and clinical differences.
The INITIATOR outcomes study, building on
current results, aims to address the
discrepancies in the baseline demographics
and clinical characteristics by selecting
patients who could be considered failing on
their OAD therapy, with A1C C7.0%, and then
further matching the patients on their baseline
characteristics to remove the selection bias seen
here. This follow-up study will then be able to
more accurately compare the outcomes
between the cohorts.
One of the strengths of the current study is
that is it based on real-world data, using both
clinical and economic information from
patients with T2DM from two large national
US claims databases. Thus, the results reflect
actual practice rather than the controlled
conditions of clinical trials and may be more
applicable to conditions faced by health care
providers in the real-world setting. The findings
of the current analysis are supported by the
consistency in patient characteristics and
outcomes between the two, large, independent
insurer databases, despite some discrepancies in
the two populations at baseline. The HC
database had a higher mean age, with a higher
percentage of patients aged 75 years or older;
this is likely due to the inclusion of Medicare
Advantage patients in this database. There is
also a disparity in the diagnosis of
hyperlipidemia between the databases,
although the baseline prevalence of
hyperlipidemia is consistently higher among
liraglutide patients. Variation in the A1C
distribution between the two databases was
observed as well, with more patients
exhibiting an A1C C9.0% in the OI database
than in the HC database. As a consequence of
the differences in their baseline characteristics,
patients from the two databases may be
representative of different populations and
exhibit different outcomes.
Interpreting results from this study is limited
by its retrospective, observational design, as the
data may be subject to selection bias and
confounding and cannot be used to establish
causality of drug effect on observed outcomes.
In addition, the analyses were based on data
from a managed care population, and they may
not be representative of other populations or
generalizable to all patients with T2DM. Also,
Medicare Advantage patients may be different,
both from commercially insured patients and
from patients on Medicare Supplemental or Part
D only. While pharmaceutical claims provide
information on the type and dosage of the
prescribed medication, no information was
available regarding a patient’s actual daily
usage of medication, and, therefore, treatment
persistence could only be estimated from
pharmacy claims data. The presence of a claim
for a filled prescription does not indicate
whether the medication was actually used or
that it was administered as prescribed.
Furthermore, this study was conducted on
health care claims data that are potentially
subject to coding errors. Health care claims
Adv Ther (2013) 30:1128–1140 1137
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data also pose difficulties in obtaining complete
medical histories; for example, these databases
did not have information on patients’ weight
and BMI.
CONCLUSION
The interim analysis from this real-world study
showed significant baseline differences between
T2DM patients initiating liraglutide and insulin
glargine, suggesting that these agents are being
used to treat different patient groups. Insulin
glargine is prescribed for patients with less well
controlled diabetes who are in need of larger
A1C reduction, whereas liraglutide is given to
patients with better glycemic control, with
weight loss as an apparent treatment goal for
some patients. The substantial differences in
demographic and baseline clinical
characteristics may confound comparative
effectiveness research. The next phase of the
INITIATOR study will assess outcomes after
accounting for these differences in patient
groups. While both types of injectable therapy
are associated with increased pharmacy costs,
total diabetes-related costs were not affected in
glargine users but were increased in liraglutide
users, suggesting further cost-effectiveness
analysis is warranted.
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